Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: REGENXBIO Inc., 3 years.
REGENXBIO Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Merck & Company Inc. | Option exercise | +41,494 | $117.89 | $4,891,728 |
| Aug 12, 2026 | Merck & Company Inc. | Option exercise | +13,433 | $84.71 | $1,137,909 |
| Aug 12, 2026 | Merck & Company Inc. | Open-market sale | −80,315 | $133.46 | $10,718,495 |
| May 29, 2026 | REGENXBIO Inc. | Grant or award | +9,807 | — | — |
| Apr 29, 2026 | Merck & Company Inc. | Option exercise | +2,951 | $110.03 | $324,699 |
| Apr 29, 2026 | Merck & Company Inc. | Shares withheld for tax | −1,454 | $110.03 | $159,984 |
| Feb 9, 2026 | Merck & Company Inc. | Option exercise | +25,946 | $119.15 | $3,091,466 |
| Feb 9, 2026 | Merck & Company Inc. | Open-market sale | −25,946 | $119.15 | $3,091,466 |
| Feb 9, 2026 | Merck & Company Inc. | Option exercise | +56,792 | $119.15 | $6,766,767 |
| Feb 9, 2026 | Merck & Company Inc. | Open-market sale | −56,792 | $119.15 | $6,766,767 |
| Feb 9, 2026 | Merck & Company Inc. | Option exercise | +38,835 | $119.15 | $4,627,190 |
| Feb 9, 2026 | Merck & Company Inc. | Open-market sale | −38,835 | $119.15 | $4,627,190 |
| Jan 26, 2026 | Merck & Company Inc. | Grant or award | +11,583 | $107.40 | $1,244,014 |
| May 30, 2025 | REGENXBIO Inc. | Grant or award | +7,768 | — | — |
| Jan 27, 2025 | Merck & Company Inc. | Grant or award | +25,423 | $97.94 | $2,489,929 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.